• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1型人类免疫缺陷病毒复制适应性的临床意义

Clinical significance of human immunodeficiency virus type 1 replication fitness.

作者信息

Dykes Carrie, Demeter Lisa M

机构信息

Infectious Diseases Division, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.

出版信息

Clin Microbiol Rev. 2007 Oct;20(4):550-78. doi: 10.1128/CMR.00017-07.

DOI:10.1128/CMR.00017-07
PMID:17934074
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2176046/
Abstract

The relative fitness of a variant, according to population genetics theory, is that variant's relative contribution to successive generations. Most drug-resistant human immunodeficiency virus type 1 (HIV-1) variants have reduced replication fitness, but at least some of these deficits can be compensated for by the accumulation of second-site mutations. HIV-1 replication fitness also appears to influence the likelihood of a drug-resistant mutant emerging during treatment failure and is postulated to influence clinical outcomes. A variety of assays are available to measure HIV-1 replication fitness in cell culture; however, there is no agreement regarding which assays best correlate with clinical outcomes. A major limitation is that there is no high-throughput assay that incorporates an internal reference strain as a control and utilizes intact virus isolates. Some retrospective studies have demonstrated statistically significant correlations between HIV-1 replication fitness and clinical outcomes in some patient populations. However, different studies disagree as to which clinical outcomes are most closely associated with fitness. This may be in part due to assay design, sample size limitations, and differences in patient populations. In addition, the strength of the correlations between fitness and clinical outcomes is modest, suggesting that, at present, it would be difficult to utilize these assays for clinical management.

摘要

根据群体遗传学理论,一个变异体的相对适合度是指该变异体对连续世代的相对贡献。大多数耐药的1型人类免疫缺陷病毒(HIV-1)变异体的复制适合度降低,但其中至少一些缺陷可通过第二位点突变的积累得到补偿。HIV-1复制适合度似乎也会影响治疗失败期间耐药突变体出现的可能性,并被推测会影响临床结果。有多种检测方法可用于测量细胞培养中HIV-1的复制适合度;然而,对于哪种检测方法与临床结果的相关性最佳,尚无共识。一个主要限制是,没有一种高通量检测方法能纳入内部参考菌株作为对照并使用完整的病毒分离株。一些回顾性研究表明,在某些患者群体中,HIV-1复制适合度与临床结果之间存在统计学上的显著相关性。然而,不同的研究对于哪些临床结果与适合度最密切相关存在分歧。这可能部分归因于检测设计、样本量限制以及患者群体的差异。此外,适合度与临床结果之间的相关性强度适中,这表明目前利用这些检测方法进行临床管理可能会很困难。

相似文献

1
Clinical significance of human immunodeficiency virus type 1 replication fitness.1型人类免疫缺陷病毒复制适应性的临床意义
Clin Microbiol Rev. 2007 Oct;20(4):550-78. doi: 10.1128/CMR.00017-07.
2
Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.HIV-1依非韦伦耐药突变体的相对复制适应性:与临床治疗期间的频率相关性以及核苷类耐药突变L74V对K103N + L100I降低的适应性进行补偿的证据
Virology. 2006 Sep 15;353(1):184-92. doi: 10.1016/j.virol.2006.05.021. Epub 2006 Jun 21.
3
Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.从抗逆转录病毒治疗失败患者中分离出的HIV毒株的复制能力、生物学表型及耐药性
J Med Virol. 2003 Jan;69(1):1-6. doi: 10.1002/jmv.10269.
4
Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.携带可导致非核苷类逆转录酶和整合酶链转移抑制剂耐药突变的 HIV-1 中病毒适应性和药物敏感性的改变。
J Virol. 2014 Aug;88(16):9268-76. doi: 10.1128/JVI.00695-14. Epub 2014 Jun 4.
5
Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.临床逆转录酶序列对HIV-1耐药突变体复制能力的影响。
Virology. 2001 Jul 5;285(2):193-203. doi: 10.1006/viro.2001.0920.
6
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.人类免疫缺陷病毒基因耐药性检测对治疗效果的影响研究。
Verh K Acad Geneeskd Belg. 2001;63(5):447-73.
7
Can modulation of viral fitness represent a target for anti-HIV-1 strategies?对病毒适应性的调控能否成为抗HIV-1策略的一个靶点?
New Microbiol. 2004 Jul;27(3):207-14.
8
Drug resistance, virus fitness and HIV-1 mutagenesis.耐药性、病毒适应性与HIV-1诱变
Curr Pharm Des. 2004;10(32):4065-70. doi: 10.2174/1381612043382404.
9
Implications of antiretroviral resistance on viral fitness.抗逆转录病毒耐药性对病毒适应性的影响。
Curr Opin Infect Dis. 2001 Feb;14(1):23-8. doi: 10.1097/00001432-200102000-00005.
10
Practical applications of viral fitness in clinical practice.
Curr Opin Infect Dis. 2003 Feb;16(1):11-8. doi: 10.1097/00001432-200302000-00003.

引用本文的文献

1
The Role of Drug Resistance in Candida Inflammation and Fitness.耐药性在念珠菌炎症和适应性中的作用。
Microorganisms. 2025 Jul 30;13(8):1777. doi: 10.3390/microorganisms13081777.
2
Current methods for detecting and assessing HIV-1 antibody resistance.检测和评估HIV-1抗体耐药性的当前方法。
Front Immunol. 2025 Jan 6;15:1443377. doi: 10.3389/fimmu.2024.1443377. eCollection 2024.
3
QuickFit: A High-Throughput RT-qPCR-Based Assay to Quantify Viral Growth and Fitness In Vitro.QuickFit:一种高通量基于 RT-qPCR 的检测方法,用于定量体外病毒生长和适应性。
Viruses. 2024 Aug 19;16(8):1320. doi: 10.3390/v16081320.
4
In Vitro Susceptibility of HIV Isolates with High Growth Capability to Antiretroviral Drugs.高生长能力的 HIV 分离物对抗逆转录病毒药物的体外敏感性。
Int J Mol Sci. 2022 Dec 6;23(23):15380. doi: 10.3390/ijms232315380.
5
Adaptive Mutation in the Main Protease Cleavage Site of Feline Coronavirus Renders the Virus More Resistant to Main Protease Inhibitors.猫冠状病毒主要蛋白酶切割位点的适应性突变使病毒对主要蛋白酶抑制剂更具抗性。
J Virol. 2022 Sep 14;96(17):e0090722. doi: 10.1128/jvi.00907-22. Epub 2022 Aug 24.
6
A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells.一种新型高通量、平行感染测定法,用于测定苏黎世原发性 HIV-1 感染研究中 346 株原发性 HIV-1 分离株在原代细胞中的复制能力。
Viruses. 2021 Mar 4;13(3):404. doi: 10.3390/v13030404.
7
High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.早期猿猴免疫缺陷病毒感染期间病毒群体的高分辨率测序揭示了快速逃避新出现的Env特异性抗体反应的进化策略。
J Virol. 2018 Mar 14;92(7). doi: 10.1128/JVI.01574-17. Print 2018 Apr 1.
8
Reversing resistance: different routes and common themes across pathogens.逆转耐药性:病原体的不同途径与共同主题
Proc Biol Sci. 2017 Sep 27;284(1863). doi: 10.1098/rspb.2017.1619.
9
Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression.急性感染期病毒的复制能力推动HIV-1疾病进展。
J Virol. 2017 Mar 29;91(8). doi: 10.1128/JVI.01806-16. Print 2017 Apr 15.
10
Viral envelope is a major determinant of enhanced fitness of a multidrug-resistant HIV-1 variant.病毒包膜是多重耐药性HIV-1变体适应性增强的主要决定因素。
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):487-94. doi: 10.1097/QAI.0000000000000524.

本文引用的文献

1
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.HIV-1逆转录酶中的A62V和S68G突变部分恢复了与K65R突变相关的复制缺陷。
J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):428-36. doi: 10.1097/QAI.0b013e31817bbe93.
2
Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.初治和经治患者中HIV切割位点p7/p1和p1/p6 - gag处的补偿性突变。
Antivir Ther. 2006;11(7):879-87.
3
Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.1型人类免疫缺陷病毒:对核苷类似物的耐药性及在原代人巨噬细胞中的复制能力
J Virol. 2007 May;81(9):4540-50. doi: 10.1128/JVI.01620-06. Epub 2007 Feb 7.
4
Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.在没有蛋白酶抑制剂(PI)治疗的情况下,具有多个PI耐药突变的HIV-1变体的持续存在可以通过补偿性固定来解释。
J Infect Dis. 2007 Feb 1;195(3):399-409. doi: 10.1086/510533. Epub 2006 Dec 29.
5
Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.在基于恩夫韦肽的治疗方案中,对病毒抑制不完全的HIV-1感染成人中断恩夫韦肽治疗。
J Infect Dis. 2007 Feb 1;195(3):387-91. doi: 10.1086/510531. Epub 2006 Dec 21.
6
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.在慢性HIV-1感染患者中,根据CD4细胞计数和血浆HIV-1 RNA水平指导抗逆转录病毒治疗中断。
AIDS. 2007 Jan 11;21(2):169-78. doi: 10.1097/QAD.0b013e328011033a.
7
The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.与1型人类免疫缺陷病毒耐药性相关的突变的适合度代价受突变相互作用的调节。
J Virol. 2007 Mar;81(6):3037-41. doi: 10.1128/JVI.02712-06. Epub 2006 Dec 27.
8
CD4+ count-guided interruption of antiretroviral treatment.基于CD4细胞计数指导的抗逆转录病毒治疗中断
N Engl J Med. 2006 Nov 30;355(22):2283-96. doi: 10.1056/NEJMoa062360.
9
Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity.抗逆转录病毒治疗一年后CD4 T细胞增加更多与较低的HIV-1 pol复制能力相关。
AIDS. 2006 Oct 24;20(16):2123-5. doi: 10.1097/01.aids.0000247583.38943.95.
10
A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.针对耐药性HIV感染者在优化抗逆转录病毒治疗前进行治疗中断的随机试验:ACTG A5086的48周病毒学结果
J Infect Dis. 2006 Nov 1;194(9):1309-18. doi: 10.1086/508289. Epub 2006 Sep 22.